Engineering extracellular vesicles enriched with palmitoylated ACE2 as COVID‐19 therapy

F Xie, P Su, T Pan, X Zhou, H Li, H Huang… - Advanced …, 2021 - Wiley Online Library
Abstract Angiotensin converting enzyme 2 (ACE2) is a key receptor present on cell surfaces
that directly interacts with the viral spike (S) protein of the severe acute respiratory syndrome …

Decoy ACE2-expressing extracellular vesicles that competitively bind SARS-CoV-2 as a possible COVID-19 therapy

JM Inal - Clinical Science, 2020 - portlandpress.com
The novel strain of coronavirus that appeared in 2019, SARS-CoV-2, is the causative agent
of severe respiratory disease, COVID-19, and the ongoing pandemic. As for SARS-CoV that …

[HTML][HTML] Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles

C Wu, Q Xu, H Wang, B Tu, J Zeng, P Zhao… - … Pharmaceutica Sinica B, 2022 - Elsevier
The spread of coronavirus disease 2019 (COVID-19) throughout the world has resulted in
stressful healthcare burdens and global health crises. Developing an effective measure to …

Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2

L El-Shennawy, AD Hoffmann, NK Dashzeveg… - Nature …, 2022 - nature.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the
pandemic of the coronavirus induced disease 2019 (COVID-19) with evolving variants of …

Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS‐CoV‐2 infection

HK Kim, J Cho, E Kim, J Kim, JS Yang… - Journal of …, 2022 - Wiley Online Library
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) entry is mediated by the
interaction of the viral spike (S) protein with angiotensin‐converting enzyme 2 (ACE2) on the …

Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection

L Guo, W Bi, X Wang, W Xu, R Yan, Y Zhang, K Zhao… - Cell Research, 2021 - nature.com
Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in a severe global pandemic. Following …

SARS-CoV-2 cellular entry is independent of the ACE2 cytoplasmic domain signaling

T Karthika, J Joseph, VRA Das, N Nair, P Charulekha… - Cells, 2021 - mdpi.com
Recently emerged severe acute respiratory syndrome coronavirus (SARS-CoV)-1 and-2
initiate virus infection by binding of their spike glycoprotein with the cell-surface receptor …

[HTML][HTML] Soluble ACE2 as a potential therapy for COVID-19

S Krishnamurthy, RF Lockey… - American Journal of …, 2021 - journals.physiology.org
Soluble angiotensin-converting enzyme 2 (sACE2) could be a therapeutic option to treat
coronavirus disease 2019 (COVID-19) infection. Severe acute respiratory syndrome …

[HTML][HTML] An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages

S Satta, Z Meng, R Hernandez, S Cavallero, T Zhou… - Theranostics, 2022 - ncbi.nlm.nih.gov
Rationale: Macrophages are the frontline immune cells in response to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Angiotensin-converting …

ACE2: its potential role and regulation in severe acute respiratory syndrome and COVID‐19

M Rezaei, SA Ziai, S Fakhri… - Journal of cellular …, 2021 - Wiley Online Library
COVID‐19, a new disease caused by the 2019‐novel coronavirus (SARS‐CoV‐2), has
swept the world and challenged its culture, economy, and health infrastructure. Forced …